HIV-tuberculosis coinfection: Difference between revisions

From IDWiki
No edit summary
()
 
(One intermediate revision by the same user not shown)
Line 12: Line 12:
*Regimens that minimize drug-drug interactions:
*Regimens that minimize drug-drug interactions:
**[[Efavirenz]] 600 mg PO daily or [[raltegravir]] 400 mg PO bid, combined with [[abacavir]]/[[lamivudine]] or [[tenofovir disoproxil fumarate]]/[[emtricitabine]]
**[[Efavirenz]] 600 mg PO daily or [[raltegravir]] 400 mg PO bid, combined with [[abacavir]]/[[lamivudine]] or [[tenofovir disoproxil fumarate]]/[[emtricitabine]]
**[[tenofovir disoproxil fumarate]]/[[emtricitabine]] + [[efavirenz]]
**[[Tenofovir disoproxil fumarate]]/[[emtricitabine]] + [[efavirenz]]
**[[tenofovir disoproxil fumarate]]/[[emtricitabine]] + double [[raltegravir]]
**[[Tenofovir disoproxil fumarate]]/[[emtricitabine]] + double [[raltegravir]]
**[[Abacavir]]/[[lamivudine]] with BID [[dolutegravir]]
**[[Abacavir]]/[[lamivudine]] with BID [[dolutegravir]]
**[[Tenofovir alafenamide]] may or may not be affected by [[rifampin]]
**[[Tenofovir alafenamide]] may or may not be affected by [[rifampin]]
Line 19: Line 19:
**Start TB treatment immediately
**Start TB treatment immediately
**If not already on HIV treatment:
**If not already on HIV treatment:
***CD4 count <50 cells/mm<sup>3</sup>: start as soon as possible, and within 2 weeks of TB treatment
***CD4 count <50 cells/mm<sup>3</sup>: start HIV treatment as soon as possible, and within 2 weeks of TB treatment
***CD4 count ≥50 cells/mm<sup>3</sup>: start within 8 weeks of TB treatment
***CD4 count ≥50 cells/mm<sup>3</sup>: start HIV treatment within 8 weeks of TB treatment
***Pregnancy, regardless of CD4: start as soon as feasible, to prevent transmission
***Pregnancy, regardless of CD4: start as soon as feasible, to prevent transmission
**With tuberculous meningitis, monitor closely when starting early
**With tuberculous meningitis, generally defer to 8 weeks, or monitor closely when starting early


[[Category:HIV]]
[[Category:HIV]]

Latest revision as of 18:49, 5 January 2022

Management

Latent Tuberculosis Infection

Active Tuberculosis